HSPC038 inhibitors are small molecules that target and inhibit the function of HSPC038, a kinase involved in multiple intracellular signaling pathways. These inhibitors are typically designed to interact with the ATP-binding pocket of HSPC038, disrupting its kinase activity and preventing downstream signal transduction. The chemical structure of HSPC038 inhibitors usually includes a scaffold that facilitates binding to the kinase domain with high specificity and affinity. They often incorporate hydrophobic moieties and heterocyclic structures that contribute to binding interactions, and additional functional groups may enhance solubility or bioavailability. Many of these inhibitors are designed to achieve optimal selectivity for HSPC038 over other kinases to ensure that off-target effects are minimized and the primary biological activity is maintained. Structure-activity relationship (SAR) studies are commonly conducted to refine these chemical features, optimizing binding and inhibitory potency against HSPC038.
The mechanism of action of HSPC038 inhibitors generally involves competitive inhibition, where the compound competes with ATP for binding to the kinase. This binding disrupts the kinase's ability to phosphorylate substrates, effectively halting the downstream signaling cascades associated with HSPC038. The design of these inhibitors may involve rigidifying molecular conformations to fit the active site of HSPC038 precisely, ensuring that they can achieve tight binding and prolonged inhibitory effects. The chemical class of HSPC038 inhibitors is characterized by a diverse range of molecular structures that all serve the same function: selective inhibition of HSPC038 kinase activity. Modifications to these structures can alter their pharmacokinetic properties and binding affinities, leading to a variety of compounds within this class that have distinct inhibitory profiles. Furthermore, the continued development of HSPC038 inhibitors is focused on enhancing specificity, potency, and stability to better understand the role of HSPC038 in cellular signaling pathways and its broader biological functions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase (HDAC) inhibitor. By inhibiting HDACs, TSA can alter chromatin structure, potentially influencing the binding and regulatory activities of transcription factors like ZNF706. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor. It can modify the methylation status of DNA, potentially affecting transcriptional regulation and the activities of DNA-binding proteins, possibly including ZNF706. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
Another DNA methyltransferase inhibitor. Similar to 5-Azacytidine, RG108 can alter DNA methylation, potentially influencing ZNF706's transcriptional regulatory functions. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
Bromodomain inhibitor, targeting BET family proteins, which affects transcriptional elongation. Might influence the regulatory roles of transcription factors, possibly including ZNF706. | ||||||
GSK 525762A | 1260907-17-2 | sc-490339 sc-490339A sc-490339B sc-490339C sc-490339D | 5 mg 10 mg 50 mg 100 mg 1 g | $300.00 $540.00 $940.00 $1680.00 $5900.00 | ||
Another BET bromodomain inhibitor, impacting transcription. Could influence DNA-binding proteins like ZNF706 by altering transcriptional landscapes. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
MDM2-p53 interaction inhibitor. If ZNF706 plays any role in p53-mediated transcriptional responses, Nutlin-3 might have an indirect effect. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor. Given the role of JNK in transcriptional stress responses, inhibiting it might have repercussions on transcription factors and their targets, potentially including ZNF706. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor. Given PI3K's role in many cellular processes including transcription, it could influence transcription factors or co-regulators in pathways that ZNF706 is involved in. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor. Like LY294002, wortmannin can impact pathways influencing transcriptional regulation, potentially affecting ZNF706. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Topoisomerase II inhibitor. It interferes with DNA topology and can affect transcription, possibly influencing the binding or regulatory activities of proteins like ZNF706. | ||||||